17:42:58 EDT Sun 21 Oct 2018
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:EXEL - Exelixis, Inc. - http://www.exelixis.com17:42:58 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EXEL - Q0.316.00 · 16.880.316.27-0.25-1.53,764.161,54517,11516.62  16.92  16.1832.20  15.4917:46:28Oct 1815 min RT 2¢

Recent Trades - Last 10 of 17115
Time ETExPriceChangeVolume
17:46:28Q16.700.181
17:14:08Q16.560.043
16:38:51Q16.3565-0.1635153,170
16:23:40Q16.27-0.253
16:09:37Q16.27-0.2562
16:08:19Q16.27-0.2530
16:00:09Q16.27-0.25200
16:00:04Q16.27-0.25198
16:00:03Q16.27-0.25100
16:00:03Q16.27-0.25600

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2018-10-20 08:45U:EXELNews ReleaseExelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
2018-10-18 16:05U:EXELNews ReleaseExelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
2018-10-17 08:30U:EXELNews ReleaseReport: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications — New Horizons, Emerging Trends, and Upcoming Developments
2018-10-08 18:05U:EXELNews ReleaseCabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
2018-10-08 08:00U:EXELNews ReleaseExelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
2018-09-25 16:05U:EXELNews ReleaseExelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018